Rebecca Marnocha
- Oncology top 5%
- Cancer Treatment and Pharmacology 12
- Peptidase Inhibition and Analysis 6
- Colorectal Cancer Treatments and Studies 3
- Immunology and Allergy top 10%
- Cancer Research top 10%
- Molecular Biology top 10%
- Cancer therapeutics and mechanisms 7
- Histone Deacetylase Inhibitors Research 5
- Protein Degradation and Inhibitors 5
-
- Renal cell carcinoma treatment 3
- Prostate Cancer Treatment and Research 3
- Co-authors
- George WildingDona AlbertiKendra D. TutschRhoda ArzoomanianJens C. EickhoffJill KolesarJames P. ThomasHoward H. Bailey
- Journals
- Journal of Clinical Oncology (7 papers)SHILAP Revista de lepidopterología (1 paper)Cancer (1 paper)
- Partner nations
- United StatesSpainCanada
In The Last Decade
Rebecca Marnocha
35 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 100
- Oncology 476
- Immunology and Allergy 84
- Cancer Research 203
- Molecular Biology 726
- Immunology 208
Countries citing papers authored by Rebecca Marnocha
This map shows the geographic impact of Rebecca Marnocha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebecca Marnocha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebecca Marnocha more than expected).
Fields of papers citing papers by Rebecca Marnocha
This network shows the impact of papers produced by Rebecca Marnocha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebecca Marnocha. The network helps show where Rebecca Marnocha may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Rebecca Marnocha, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 3 | |
| 2 | 2017 | 45 | |
| 3 | 2013 | 24 | |
| 4 | 2013 | 39 | |
| 5 | 2010 | 17 | |
| 6 | 2009 | 6 | |
| 7 | 2008 | 16 | |
| 8 | 2008 | 30 | |
| 9 | 2008 | 13 | |
| 10 | 2006 | 1 | |
| 11 | 2005 | 9 | |
| 12 | 2005 | 2 | |
| 13 | 2004 | 25 | |
| 14 | 2003 | 21 | |
| 15 | 2003 | 3 | |
| 16 | 2002 | 100 | |
| 17 | Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy. | 2002 | 2 |
| 18 | Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. | 2002 | 57 |
| 19 | 2001 | 16 | |
| 20 | 1992 | 11 |
About Rebecca Marnocha
Rebecca Marnocha is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 35 papers that have together received 1.3k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (12 papers), Cancer therapeutics and mechanisms (7 papers), Peptidase Inhibition and Analysis (6 papers), Histone Deacetylase Inhibitors Research (5 papers), Protein Degradation and Inhibitors (5 papers), Renal cell carcinoma treatment (3 papers), Colorectal Cancer Treatments and Studies (3 papers) and Prostate Cancer Treatment and Research (3 papers). The work is most often cited by research in Oncology (476 citations), Immunology and Allergy (84 citations) and Cancer Research (203 citations). Rebecca Marnocha has collaborated with scholars based in United States, Spain and Canada. Frequent co-authors include George Wilding, Dona Alberti, Kendra D. Tutsch, Rhoda Arzoomanian, Jens C. Eickhoff, Jill Kolesar, James P. Thomas, Howard H. Bailey, Glenn Liu and Douglas G. McNeel. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.